Myths vs. Facts: China, Biotech, and National Security
Are American biotech companies really sending $120 billion to China? And could restricting U.S. investment weaken America's position in the global biotech industry?
As Washington debates biotechnology investment restrictions and national security, Making Medicine host John Stanford examines five common claims shaping the conversation about China, pharmaceutical innovation, and American competitiveness.
From the economics of biotech licensing agreements to the role of American venture capital, this episode explores what the headlines may be missing, and why the distinction between announced…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.